01 1Cipla
01 1BICTEGRAVIR SODIUM
01 1India
01 1Active
01 1Complete
GDUFA
DMF Review : Complete
Rev. Date : 2021-07-06
Pay. Date : 2021-05-28
DMF Number : 35866
Submission : 2021-05-24
Status : Active
Type : II
20
Cipla Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is BICTEGRAVIR SODIUM, with a corresponding US DMF Number 35866.
Remarkably, this DMF maintains an Active status since its submission on May 24, 2021, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of July 06, 2021, and payment made on May 28, 2021, indicating their dedication to facilitating drug approvals, Categorized as Type II
